HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE.Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.
Ecallantide is a recombinant peptide inhibitor that specifically targets plasma kallikrein, a serine protease integral to the kallikrein-kinin system. As a 60-amino acid protein, it is structurally characterized by its potent and selective binding to the active site of plasma kallikrein, thereby modulating pathways related to bradykinin generation and contact system activation. The unique inhibitory profile and high specificity of ecallantide have made it a valuable tool in research focused on the regulation of proteolytic cascades, vascular permeability, and inflammatory mediator release within biochemical and physiological contexts.
Protease inhibition studies: Ecallantide serves as a precise molecular probe for investigating the functional dynamics of plasma kallikrein in vitro and in vivo. By providing targeted inhibition, it enables researchers to dissect the role of kallikrein in proteolytic signaling pathways, including the initiation of the intrinsic coagulation cascade and the regulation of bradykinin-mediated responses. Its use facilitates mechanistic studies that require selective suppression of kallikrein activity without broadly affecting related serine proteases, thus supporting the elucidation of protease-specific events in complex biological systems.
Inflammatory pathway research: The compound is widely employed in studies exploring the molecular mechanisms underlying inflammation, particularly those involving the kallikrein-kinin system. By modulating bradykinin production, ecallantide allows for controlled examination of vascular permeability, edema formation, and the interplay between contact system components and downstream inflammatory mediators. Its application is instrumental in distinguishing kallikrein-dependent from kallikrein-independent processes, thereby advancing the understanding of inflammatory signaling networks.
Biochemical assay development: Ecallantide is frequently utilized as a reference inhibitor in the development and validation of biochemical assays aimed at quantifying plasma kallikrein activity. Its well-defined inhibitory kinetics and specificity make it an ideal positive control in enzymatic assays, high-throughput screening platforms, and inhibitor profiling studies. The compound's inclusion ensures assay accuracy and reliability, supporting the identification of novel modulators of the kallikrein-kinin system for basic and applied research purposes.
Contact system and vascular biology studies: The selective action of ecallantide on plasma kallikrein positions it as a critical reagent in studies of the contact activation system and its impact on vascular biology. Researchers leverage its inhibitory properties to explore the regulation of vascular tone, permeability, and the pathological consequences of dysregulated contact system activation. Its use aids in defining the contributions of kallikrein to endothelial function, microvascular leakage, and the broader context of hemostatic balance.
Pharmacological mechanism elucidation: In preclinical research, ecallantide provides a model for understanding the pharmacological consequences of selective kallikrein inhibition. By enabling controlled modulation of the kallikrein-kinin axis, it supports investigations into the downstream effects on cellular signaling, mediator release, and systemic physiological responses. These studies contribute to a more nuanced appreciation of serine protease regulation and inform the rational design of next-generation inhibitors targeting the kallikrein-kinin pathway for research applications.
Ecallantide (Kalbitor [previously, DX-88]; Dyax, Cambridge, MA) is a recombinant protein synthesized in the yeast Pichia pastoris. Ecallantide is a potent and specific inhibitor of plasma kallikrein. In phase 2 trials, symptoms of angioedema improved within 4 hours after treatment with ecallantide.18,21 The Evaluation of DX-88's Effects in Mitigating Angioedema (EDEMA) 3 trial was a randomized, placebo-controlled, phase 3 evaluation of ecallantide for the treatment of acute attacks of angioedema in patients with hereditary angioedema.
Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, debilitating, and potentially fatal disease characterized by acute attacks of swelling that can affect the abdomen/gastrointestinal tract, larynx, face, genitals, and extremities. Ecallantide is a novel plasma kallikrein inhibitor developed for the treatment of acute HAE attacks. Ecallantide provides relief of acute HAE attack symptoms, with rapidity of response commensurate with therapeutic needs for HAE attack locations.
Response time for ecallantide treatment of acute hereditary angioedema attacks
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More